Meet One-on-One with... National Cancer Institute | One-on-One meeting registration

Add this event to your calendar:
06/08/2015 14:00 06/08/2015 16:00 America/New_York Meet One-on-One with... National Cancer Institute | One-on-One meeting registration JLABS @LabCentral , 700 Main Street , Cambridge , MA 02139 Johnson & Johnson Innovation, JLABS false DD/MM/YYYY

Meet One-on-One with... National Cancer Institute | One-on-One meeting registration

JLABS @LabCentral , 700 Main Street , Cambridge , MA 02139

August 06, 2015 from 14:00 PM to 16:00 PM (EST)

$10 - $35

JLABS EVENT Congratulations! You have been approved to attend a one-on-one meeting with NCI. To secure your time slot please register your team who will be in attendance. After receiving confirmation of your registration you will be notified of your meeting time slot.

Note: Two registrations are required in order to attend the presentation & lunch, and the one-on-one meeting. After registering here for your one-on-one meeting, and if you have not done so yet, please register at

NCI SBIR & STTR: Advancing the Commercialization of New Cancer Innovations
Twice as many people survived cancer in 2012 than did in 1992. Today, the National Cancer Institute (NCI) is poised to further accelerate the rate of scientific discovery and reduce the burden of cancer in the United States and around the world.

Michael Weingarten, Director for the NCI SBIR Development Center, Andrew Kurtz, Program Director & Team Leader with the NCI SBIR Development Center, and Todd Haim, Program Director with the NCI SBIR Development Center will present and discuss the SBIR and STTR programs that fund and support small biomedical technology companies. These representatives will cover:

  • NIH/NCI SBIR Overview and Initiatives, as well as eligibility requirements
  • NIH SBIR/STTR process and new cancer-focused grant funding opportunities from NCI
  • New NCI SBIR/STTR initiatives such as NIH Innovation Corps (I-Corps™) Team Training Pilot Program
  • NCI efforts to help NCI SBIR-funded companies to connect with investors, venture capitalists, strategic partners, and business leaders from the biotech and pharmaceutical industries
  • Practical strategies on how to successfully submit competitive research proposals

Following the presentation and Q&A, don't miss this opportunity to introduce yourself to the NCI SBIR Development Center representatives during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with will provide a forum to further discuss your company with the NCI.

Don't miss the opportunity to meet one-on-one with directors from the NCI SBIR Development Center!

9:00am | Registration Opens
9:30am | Presentation: NIH/NCI SBIR Overview and Initiatives
10:30am | Presentation: Tips on Submitting Competitive Applications
11:15am | Networking Lunch
12:00-2:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ended July 20, 2015.

National Cancer Institute Participating Representatives:
Todd Haim | Program Director, SBIR Development Center, National Cancer Institute read bio»
Andrew Kurtz | Program Director & Team Leader, SBIR Development Center, National Cancer Institute read bio»
Michael Weingarten | Director, SBIR Development Center, National Cancer Institute read bio»

About the National Cancer Institute:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until August 5th or sold out.

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period closed on July 20, 2015.

JLABS @LabCentral
700 Main Street
Cambridge, MA 02139

National Cancer Institute Representatives' Biographies:
Todd Haim Todd Haim, Ph.D. | Program Director, SBIR Development Center, National Cancer Institute
Dr. Todd Haim is a Program Director at the National Cancer Institute's SBIR Development Center. Dr. Haim manages SBIR & STTR grants and contracts focused on the development of novel cancer therapeutics, preventative agents, and drug discovery technologies that incorporate the tumor microenvironment. Additionally, Todd plays a key role in the planning, design, and leadership of several center initiatives, including serving as coordinator of the NCI Investor Forum, helping to implement relevant workshops, draft targeted solicitations, and facilitate external partnerships. Prior to starting in the SBIR Development Center, he was a Research Associate and Christine Mirzayan Science and Technology Policy Fellow at the National Academy of Sciences. Dr. Haim staffed the Committee on Science, Engineering and Public Policy (COSEPUP) and his efforts centered on follow-up activities to the 2005 "Rising Above the Gathering Storm" report related to various innovation initiatives and evaluation programs. Previously, he completed a postdoctoral fellowship at Pfizer in which he actively led Pfizer's research efforts in a collaboration with Washington University School of Medicine in St. Louis that illustrated a mechanism for altered cardiac contractility due to excess fatty acids. Dr. Haim graduated from Albert Einstein College of Medicine in January 2007 with a PhD in biomedical research and obtained a certificate in technology commercialization from John Hopkins' Carey Business School in 2011. He has received several prestigious awards and honors including the 2014 NCI Leadership Development Award, a 2014 NIH Director's Award and the NJ Governor's Award for Volunteerism in the Field of Health.
Connect with Todd: Connect on LinkedIn

Andrew Kurtz Andrew Kurtz, Ph.D. | Program Director & Team Leader, SBIR Development Center, National Cancer Institute
Dr. Kurtz is a founding member of the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI), where he serves as Program Director and Team Leader. He manages a portfolio of small business awards and coordinates activities in the areas of drug development, clinical diagnostics, and molecular analysis technologies. In 2009, Dr. Kurtz led the development of NCI's SBIR Phase IIB Bridge award, and he continues to oversee this matching funds program, which is designed to incentivize partnerships between SBIR/STTR awardees and third-party investors, in order to accelerate the commercialization of cancer technologies seeded with Federal funding. In 2014, Dr. Kurtz played a leading role in establishing the Innovation Corps (I-Corps™) at NIH Pilot Program, an intensive entrepreneurship training course that teaches NIH-funded SBIR/STTR awardees to use a hypothesis-driven method of customer discovery toward developing a repeatable and sustainable business model. From 2005-2007, Dr. Kurtz served as a AAAS Science and Technology Policy Fellow at the NCI, where he helped to launch The Cancer Genome Atlas (TCGA) Pilot Project and developed policy recommendations to enhance the NIH SBIR/STTR programs. Before coming to the NCI, Dr. Kurtz worked in industry developing high-throughput bioanalytical assays to support pharmacokinetic studies for the biopharmaceutical sector. Dr. Kurtz received a BS in Chemistry from The University of Texas at Austin and a PhD in Biochemistry and Molecular Biology from The University of Texas Medical Branch (UTMB) at Galveston. He also holds an MIT Sloan Executive Certificate in Strategy and Innovation.
Connect with Andrew: Connect on LinkedIn

Michael Weingarten Michael Weingarten, M.S. | Director, SBIR Development Center, National Cancer Institute
Michael Weingarten is the Director for the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute in Bethesda, MD. In this role, Mr. Weingarten leads a team of nine Program Directors who manage all aspects of the NCI SBIR & STTR Programs including a portfolio of $120M in grants and contracts annually. The SBIR & STTR programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Mr. Weingarten has implemented a set of key initiatives for optimizing the performance of the NCI SBIR Program at the NIH. These include the establishment of a new model at the NCI for managing the program - the SBIR Development Center. Under Mr. Weingarten's leadership, the NCI SBIR Development Center has launched a range of new initiatives to facilitate the success of small businesses developing cancer-related technologies. Recent initiatives include the launch of the NIH I-Corps™ pilot program in which teams of budding entrepreneurs engage in a hypothesis-driven approach to validate their proposed business models by conducting over 100 interviews with potential customers. Companies adjust their strategies based on direct customer feedback and analyze the information they collect to determine if there is a product/market fit. Other NCI SBIR initiatives introduced under Mr. Weingarten's leadership include the NCI SBIR Investor Forums, the NCI SBIR Phase II Bridge Award, and the workshop titled Federal Resources to Accelerate Commercialization (FRAC) . Thus far, NCI SBIR has held three investor forums that in total have facilitated the closing of deals valued at over $300M. The NCI SBIR Phase II Bridge Award, which was launched in 2009, incentivizes partnerships between NIH's SBIR Phase II awardees and third-party investors and/or strategic partners to help small businesses bridge the funding gap between the end of their SBIR Phase II awards and the next round of financing needed to advance a promising cancer therapy or imaging technology.
Connect with Michael: Connect on LinkedIn

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

Johnson & Johnson Innovation, JLABS

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), New York City, and with Shanghai opening in 2019. For more information please visit or follow @JLABS.

Event contact

Related content